| 产品名称 | Peptides EP07741_1 | HPV 16/18 E7 49-57 (H-2 Db) |
|---|---|
| 目录号 | EP07741_1 |
| 别名 | HPV 16/18 E7 49-57 (H-2 Db) |
| 外观 | 见COA |
| 分子量 | N/A |
| CAS | N/A |
| 溶解度 | |
| 存储条件 | 见COA |
| 保存时间 | 见COA |
| 备注1 | |
| 备注2 |
| 目录号 | 规格 | 价格 | 库存状态 | |
| EP07741_1 | 1 mg; 5 mg | 咨询 | 咨询 |
Peptides EP07741_1 | HPV 16/18 E7 49-57 (H-2 Db)
品名:HPV 16/18 E7 49-57 (H-2 Db)
货号:EP07741_1
规格:1 mg; 5 mg
品牌:Peptides.de
产品描述
RAHYNIVTF is a well-characterized linear epitope derived from residues 49 to 57 of the E7 oncoprotein of Human papillomavirus type 16 (HPV-16, UniProt: P03129), as well as the homologous sequence from HPV-18 (UniProt: P06788). This H-2 Db-restricted peptide is catalogued under epitope ID 53112. Widely recognized for its robust immunogenicity in murine models, RAHYNIVTF has been investigated in over a hundred scientific publications. It has been tested in T cell assays, especially, but also in B cell assay and MHC ligand binding assays. Its widespread use in immunological studies makes it one of the most thoroughly validated HPV E7 epitopes available. This peptide has been evaluated across a diverse range of functional T cell assays, including: Cytotoxicity and T cell activation TNF-α, IL-2, IL-4, IL-10, TGF-β, and granzyme B release Proliferation and degranulation assays Pathogen and tumor burden post-challenge Survival outcomes in viral or tumor models Adoptive transfer and protection assays Due to its proven utility in preclinical tumor models and viral immunity research, RAHYNIVTF serves as a key tool for studying antigen-specific CD8⁺ T cell responses in the context of HPV-related cancer immunotherapy and vaccine development. This peptide is in stock and available for immediate delivery.
| Protein | Protein E7 |
| Species | HPV 16, HPV 18 |
| Application | Flow Cytometry |
| Indication | Infectious disease, Cancer |